Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. DeFilipp Z, Kim HT, Knight LW, O'Connor SM, et al. Blood 2025 Mar 19:blood.2024028005. doi: 10.1182/blood.2024028005.

Read + Share

Amedeo Smart

Independent Medical Education

DeFilipp Z, Kim HT, Knight LW, O'Connor SM, et al. Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT. Blood 2025 Mar 19:blood.2024028005. doi: 10.1182/blood.2024028005.
PMID: 40106768